Pityriasis Rosea is Associated with Systemic Active Infection with Both Human Herpesvirus-7 and Human Herpesvirus-6

Takahiro Watanabe(Nagoya University), Jodi B. Black(Bucknell University), Elisabeth A. Aquilino(Washington Center), Andrew Blauvelt(Oregon Medical Research Center), Jan M. Orenstein(George Washington University), Tatsuyoshi Kawamura(University of Yamanashi), Sharon E. Jacob(Howard Hughes Medical Institute)
Journal of Investigative Dermatology
October 1, 2002
10.1046/j.1523-1747.2002.00200.x
Cited by 187

Related Papers

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
|Clinical Reviews in Allergy & Immunology|2018|738
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
|The Lancet|2015|566
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
|The Lancet|2021|538